Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Helix BioPharma ( (TSE:HBP) ) has shared an update.
Helix BioPharma Corp. has postponed its Annual General and Special Meeting to March 26, 2025, to allow more time for shareholder approval on significant asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG, along with a proposed financing strategy. This extension, supported by the Toronto Stock Exchange and pending a court application, highlights Helix’s strategic efforts to enhance its operational capabilities and financial structure, which could potentially strengthen its position in the oncology sector.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing treatments for hard-to-treat cancers. The company operates in the biotechnology industry, with a market focus on innovative cancer therapies.
YTD Price Performance: 10.11%
Average Trading Volume: 5,308
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$51.96M
For a thorough assessment of HBP stock, go to TipRanks’ Stock Analysis page.
